Skip to main navigation

Main navigation

Patients
Science
- Our Scientific Approach
- Publications & Presentations
Programs
- Our Pipeline
- Mavacamten
- MYK-224
- LUS-1
- MYK-491
- ACT-1
Researchers
- For Researchers
- Grants & Funding
Investors
Careers
- Become a Myokardian
- Current Opportunities
About

Investors & Media

Price Change(%) Volume

Price Change(%) Volume

Menu

Press Releases
Events & Presentations
Stock Information
Filings & Financials
Analyst Coverage
Corporate Governance
Investor FAQ
Online Investor Kit

Press Releases

Year

MyoKardia Appoints William Fairey as Chief Commercial Officer

January 23, 2019

MyoKardia to Present at 37th Annual J.P. Morgan Healthcare Conference

January 3, 2019

MyoKardia Regains Global Rights to Mavacamten and MYK-491 Programs from Sanofi

January 2, 2019

Pagination

First page
Previous page
Page 1
Page 2
Page 3
Current page 4

Displaying 31 - 33 of 33

SHAREHOLDER TOOLS

PRINT PAGE
E-MAIL ALERTS
SHARE
IR CONTACT
RSS FEEDS

Facebook
Google
LinkedIn
Twitter

Our core values

Patients First
Passion for Science
Succeed Together
Imagine and Innovate
Lifelong Learning

Contact
Terms of Use
Privacy Policy

driven by the heart

© 2012-2019 MyoKardia. All rights reserved.

Main navigation

Patients
Science
- Our Scientific Approach
- Publications & Presentations
Programs
- Our Pipeline
- Mavacamten
- MYK-224
- LUS-1
- MYK-491
- ACT-1
Researchers
- For Researchers
- Grants & Funding
Investors
Careers
- Become a Myokardian
- Current Opportunities
About